Narla Shanthi, Silverberg Jonathan I
From the Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania, USA.
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Dermatitis. 2023 Sep-Oct;34(5):366-386. doi: 10.1089/derm.2022.29004.sna. Epub 2023 Feb 17.
Multiple Janus Kinase (JAK) inhibitors were developed as potential treatments for moderate-to-severe atopic dermatitis (AD). There is a substantial amount of safety data from recent trials of oral JAK inhibitors in patients with AD. However, the vast majority of safety data for oral JAK inhibitors is derived from patients with rheumatoid arthritis and other immune-mediated disorders, and is primarily derived from tofacitinib, a pan-selective JAK inhibitor. This narrative review examines safety data for oral JAK inhibitors from studies in AD and other indications. The available data do demonstrate that rare but serious and life-threatening adverse events can occur with oral JAK inhibitor treatment and should be carefully considered in therapeutic shared decision making.
多种 Janus 激酶（JAK）抑制剂被开发作为中度至重度特应性皮炎（AD）的潜在治疗方法。近期针对 AD 患者口服 JAK 抑制剂的试验产生了大量安全性数据。然而，口服 JAK 抑制剂的绝大多数安全性数据来自类风湿性关节炎和其他免疫介导疾病患者，且主要来自泛选择性 JAK 抑制剂托法替布。本叙述性综述考察了 AD 和其他适应症研究中口服 JAK 抑制剂的安全性数据。现有数据确实表明，口服 JAK 抑制剂治疗可能会发生罕见但严重且危及生命的不良事件，在治疗共同决策中应仔细考虑。
